Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 289

1.

The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial.

Singleton R, Wenger J, Klejka JA, Bulkow LR, Thompson A, Sarkozy D, Emini EA, Gruber WC, Scott DA.

Pediatr Infect Dis J. 2013 Mar;32(3):257-63. doi: 10.1097/INF.0b013e3182748ada.

PMID:
23001026
2.

13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial.

Silfverdal SA, Flodmark CE, Rombo L, Tansey SP, Sidhu M, Trammel J, Emini EA, Gruber WC, Scott DA, Gurtman A; 3012 study group..

Vaccine. 2013 Feb 18;31(9):1284-92. doi: 10.1016/j.vaccine.2012.12.066. Epub 2013 Jan 7.

PMID:
23306363
3.

Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.

Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.

Vaccine. 2013 Dec 16;31(52):6232-8. doi: 10.1016/j.vaccine.2013.10.032. Epub 2013 Oct 29.

PMID:
24176490
4.

Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska.

Bruce MG, Singleton R, Bulkow L, Rudolph K, Zulz T, Gounder P, Hurlburt D, Bruden D, Hennessy T.

Vaccine. 2015 Sep 11;33(38):4813-9. doi: 10.1016/j.vaccine.2015.07.080. Epub 2015 Aug 4.

5.

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines.

Kim DS, Shin SH, Lee HJ, Hong YJ, Lee SY, Choi KM, Oh CE, Kim KH, Juergens C, Patterson S, Giardina PC, Gruber WC, Emini EA, Scott DA.

Pediatr Infect Dis J. 2013 Mar;32(3):266-73. doi: 10.1097/INF.0b013e3182748bb6.

PMID:
23011012
6.

Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020.

Link-Gelles R, Taylor T, Moore MR; Active Bacterial Core Surveillance Team..

Vaccine. 2013 May 24;31(22):2572-7. doi: 10.1016/j.vaccine.2013.03.049. Epub 2013 Apr 11.

PMID:
23583813
7.

Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.

Diez-Domingo J, Gurtman A, Bernaola E, Gimenez-Sanchez F, Martinon-Torres F, Pineda-Solas V, Delgado A, Infante-Marquez P, Liang JZ, Giardina PC, Gruber WC, Emini EA, Scott DA.

Vaccine. 2013 Nov 4;31(46):5486-94. doi: 10.1016/j.vaccine.2013.06.049. Epub 2013 Sep 1.

PMID:
24004465
8.

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine.

Frenck R Jr, Thompson A, Yeh SH, London A, Sidhu MS, Patterson S, Gruber WC, Emini EA, Scott DA, Gurtman A; 3011 Study Group..

Pediatr Infect Dis J. 2011 Dec;30(12):1086-91. doi: 10.1097/INF.0b013e3182372c6a.

PMID:
21983216
9.

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.

Esposito S, Tansey S, Thompson A, Razmpour A, Liang J, Jones TR, Ferrera G, Maida A, Bona G, Sabatini C, Pugni L, Emini EA, Gruber WC, Scott DA, Principi N.

Clin Vaccine Immunol. 2010 Jun;17(6):1017-26. doi: 10.1128/CVI.00062-10. Epub 2010 Apr 28.

10.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan.

Togashi T, Yamaji M, Thompson A, Giardina PC, Aizawa M, Patterson S, Gruber WC, Scott DA; 3003 Study Group..

Pediatr Infect Dis J. 2013 Sep;32(9):984-9. doi: 10.1097/INF.0b013e318293007e.

PMID:
23538524
11.

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.

Vanderkooi OG, Scheifele DW, Girgenti D, Halperin SA, Patterson SD, Gruber WC, Emini EA, Scott DA, Kellner JD; Canadian PCV13 Study Group..

Pediatr Infect Dis J. 2012 Jan;31(1):72-7. doi: 10.1097/INF.0b013e318233049d.

PMID:
21960186
12.

Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.

Black S, France EK, Isaacman D, Bracken L, Lewis E, Hansen J, Fireman B, Austrian R, Graepel J, Gray S, Klein NP.

Pediatr Infect Dis J. 2007 Sep;26(9):771-7.

PMID:
17721369
13.
14.

Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark.

Harboe ZB, Valentiner-Branth P, Ingels H, Rasmussen JN, Andersen PH, Bjerre CC, Goldblatt D, Ashton L, Haston M, Konradsen HB, Lambertsen L; Danish Pneumococcal Surveillance Collaborating Group..

PLoS One. 2013;8(1):e51460. doi: 10.1371/journal.pone.0051460. Epub 2013 Jan 24.

15.

Expansion of serotype coverage in the universal pediatric vaccination calendar: short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain.

Picazo J, Ruiz-Contreras J, Casado-Flores J, Negreira S, García-de-Miguel MJ, Hernández-Sampelayo T, Otheo E, Méndez C; HERACLES Study Group..

Clin Vaccine Immunol. 2013 Oct;20(10):1524-30. doi: 10.1128/CVI.00239-13. Epub 2013 Aug 7.

16.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan.

Huang LM, Lin TY, Juergens C.

Vaccine. 2012 Mar 9;30(12):2054-9. doi: 10.1016/j.vaccine.2011.12.054. Epub 2011 Dec 22.

PMID:
22198517
17.

Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England.

Moore CE, Paul J, Foster D, Mahar SA, Griffiths D, Knox K, Peto TE, Walker AS, Crook DW; Oxford Invasive Pneumococcal Surveillance Group..

J Infect Dis. 2014 Oct 1;210(7):1001-11. doi: 10.1093/infdis/jiu213. Epub 2014 Apr 9.

PMID:
24719477
18.

Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2010 Mar 12;59(9):253-7.

19.

Invasive pneumococcal disease in Alaskan children: impact of the seven-valent pneumococcal conjugate vaccine and the role of water supply.

Wenger JD, Zulz T, Bruden D, Singleton R, Bruce MG, Bulkow L, Parks D, Rudolph K, Hurlburt D, Ritter T, Klejka J, Hennessy T.

Pediatr Infect Dis J. 2010 Mar;29(3):251-6. doi: 10.1097/INF.0b013e3181bdbed5.

PMID:
19952861
20.

A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil.

Weckx LY, Thompson A, Berezin EN, de Faria SM, da Cunha CA, Pride M, Patterson S, Gruber WC, Emini EA, Scott DA; 012 Study Group..

Vaccine. 2012 Dec 14;30(52):7566-72. doi: 10.1016/j.vaccine.2012.10.040. Epub 2012 Oct 22.

PMID:
23099331

Supplemental Content

Support Center